• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Anika Therapeutics Inc. (Amendment)

    2/14/23 10:33:01 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care
    Get the next $ANIK alert in real time by email
    SC 13G/A 1 d401798dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Amendment #2

    Under the Securities and Exchange Act of 1934

     

     

    Anika Therapeutics Inc

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    035255108

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    This Schedule is filed pursuant to Rule 13d-1(b)

    The information required in the remainder of this cover page (except any items to which the form provides a cross-reference) shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

     

     

     


    CUSIP NO. 035255108

     

      1)    

      Name of Reporting Person                                                               Ameriprise Financial, Inc.

     

      S.S. or I.R.S. Identification No. of Above Person                           IRS No. 13-3180631

      2)  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☒*

     

      *   This filing describes the reporting person’s relationship with other persons, but the reporting person does not affirm the existence of a group.

     

      3)  

      SEC Use Only

     

      4)  

      Citizenship or Place of Organization

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5)     

      Sole Voting Power

     

      0

       6)   

      Shared Voting Power

     

      151,782

       7)   

      Sole Dispositive Power

     

      0

       8)   

      Shared Dispositive Power

     

      181,943

      9)    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      181.943

    10)  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11)  

      Percent of Class Represented by Amount In Row (9)

     

      1.25%

    12)  

      Type of Reporting Person

     

      HC


    CUSIP NO. 035255108

     

      1)    

      Name of Reporting Person                                                               Columbia Management Investment Advisers, LLC

     

      S.S. or I.R.S. Identification No. of Above Person                           IRS No. 41-1533211

      2)  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☒*

     

      *   This filing describes the reporting person’s relationship with other persons, but the reporting person does not affirm the existence of a group.

     

      3)  

      SEC Use Only

     

      4)  

      Citizenship or Place of Organization

     

      Minnesota

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5)     

      Sole Voting Power

     

      0

       6)   

      Shared Voting Power

     

      151,782

       7)   

      Sole Dispositive Power

     

      0

       8)   

      Shared Dispositive Power

     

      170,152

      9)    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      170,152

    10)  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11)  

      Percent of Class Represented by Amount In Row (9)

     

      1.16%

    12)  

      Type of Reporting Person

     

      IA


    CUSIP NO. 035255108

     

      1)    

      Name of Reporting Person                                                               Columbia Wanger Asset Management, LLC

     

      S.S. or I.R.S. Identification No. of Above Person                           IRS No. 04-3519872

      2)  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☒*

     

      *   This filing describes the reporting person’s relationship with other persons, but the reporting person does not affirm the existence of a group.

     

      3)  

      SEC Use Only

     

      4)  

      Citizenship or Place of Organization

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5)     

      Sole Voting Power

     

      0

       6)   

      Shared Voting Power

     

      0

       7)   

      Sole Dispositive Power

     

      0

       8)   

      Shared Dispositive Power

     

      0

      9)    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      0

    10)  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11)  

      Percent of Class Represented by Amount In Row (9)

     

      0%

    12)  

      Type of Reporting Person

     

      IA


    1(a)    Name of Issuer:    Anika Therapeutics Inc
    1(b)    Address of Issuer’s Principal    32 Wiggins Avenue
       Executive Offices:    Bedford, MA 01730
    2(a)    Name of Person Filing:    (a) Ameriprise Financial, Inc. (“AFI”)
          (b) Columbia Management Investment Advisers, LLC (“CMIA”)
          (c) Columbia Wanger Asset Management, LLC (“CWAM”)
    2(b)    Address of Principal Business Office:   

    (a) Ameriprise Financial, Inc.

    145 Ameriprise Financial Center

    Minneapolis, MN 55474

         

    (b) 290 Congress St.

    Boston, MA 02210

         

    (c) 71 S Wacker Dr., Suite 2500

    Chicago, IL 60606

    2(c)    Citizenship:    (a) Delaware
          (b) Minnesota
          (c) Delaware
    2(d)    Title of Class of Securities:    Class A Common Stock
    2(e)    Cusip Number:    035255108

     

    3

    Information if statement is filed pursuant to Rules 13d-1(b) or 13d-2(b):

    (a) Ameriprise Financial, Inc.

    A parent holding company in accordance with Rule 13d-1(b)(1)(ii)(G). (Note: See Item 7)

    (b) Columbia Management Investment Advisers, LLC

    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

    (c) Columbia Wanger Asset Management, LLC

    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

     

    4

    Incorporated by reference to Items (5)-(9) and (11) of the cover page pertaining to each reporting person.


    AFI, as the parent company of CMIA and CWAM, may be deemed to beneficially own the shares reported herein by those reporting persons. Accordingly, the shares reported herein by AFI include those shares separately reported herein by those reporting persons.

    Each of AFI, CMIA and CWAM disclaims beneficial ownership of any shares reported on this Schedule.

     

    5

    Ownership of 5% or Less of a Class:

    If this statement is being filed to report the fact as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☒.

     

    6

    Ownership of more than 5% on Behalf of Another Person: Not Applicable

     

    7

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:

    AFI: See Exhibit I

     

    8

    Identification and Classification of Members of the Group:

    Not Applicable

     

    9

    Notice of Dissolution of Group:

    Not Applicable

     

    10

    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect.


    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 14, 2023

     

    Ameriprise Financial, Inc.
    By:  

    /s/ Michael G. Clarke

    Name: Michael G. Clarke
    Title: Senior Vice President, Head of Global Operations
    Columbia Management Investment Advisers, LLC
    By:  

    /s/ Michael G. Clarke

    Name: Michael G. Clarke
    Title: Senior Vice President, Head of Global Operations
    Columbia Wanger Asset Management, LLC
    By:  

    /s/ Joseph C. LaPalm

    Name: Joseph C. LaPalm
    Title: Chief Compliance Officer
    Contact Information
    Mark D. Braley
    Vice President
    Head of Reporting and Data Management |
    Global Operations and Investor Services
    Telephone: (617) 747-0663


    Exhibit Index

     

    Exhibit I    Identification and Classification of the Subsidiary which acquired the Security Being Reported on by the Parent Holding Company.
    Exhibit II    Joint Filing Agreement
    Get the next $ANIK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANIK

    DatePrice TargetRatingAnalyst
    4/17/2025$21.00Buy
    B. Riley Securities
    11/1/2024$37.00 → $25.00Outperform
    Barrington Research
    8/14/2023$24.00Mkt Perform → Outperform
    Barrington Research
    3/7/2023Outperform → Mkt Perform
    Barrington Research
    11/9/2022$31.00Mkt Perform → Outperform
    Barrington Research
    10/14/2022$26.00Equal-Weight
    Stephens
    3/9/2022Outperform → Mkt Perform
    Barrington Research
    3/9/2022Overweight → Equal-Weight
    Stephens & Co.
    More analyst ratings

    $ANIK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BEDFORD, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on June 2, 2025, Anika granted non-statutory stock options ("Options") covering an aggregate of 2,500 shares of common stock at a per share exercise price of $11.45, which equaled the closing price of common stock on the Nasdaq Global Select Market ("Closing Price") on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation

      6/5/25 5:00:54 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BEDFORD, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on May 1, 2025, Anika granted non-statutory stock options ("Options") covering an aggregate of 5,000 shares of common stock at a per share exercise price of $14.46, which equaled the closing price of common stock on the Nasdaq Global Select Market ("Closing Price") on the grant date, to two newly hired non-executive employees. The grants were made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, were approved by the comp

      5/12/25 5:00:24 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Anika Reports First Quarter 2025 Financial Results

      First Quarter 2025 Commercial Channel revenue up 18% Integrity™ Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Updating Fiscal 2025 OEM Channel revenue guidance and Adjusted EBITDA guidance BEDFORD, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 ResultsAnika announced first quarter reven

      5/9/25 7:05:26 AM ET
      $ANIK
      Medical/Dental Instruments
      Health Care